Monitor upcoming clinical catalysts for HLP003 (Phase 3 MDD) and HLP004 (Phase 2 GAD) — the name change itself has no trading implications.
Price Chart
Executive Summary
Helus Pharma Inc. (formerly Cybin Inc.) completed its legal name change to Helus Pharma Inc. effective October 1, 2026, following shareholder approval on September 22, 2026. The name change is administrative and does not affect the company's ticker (HELP), share structure, or trading exchanges. No financial data or operational milestones were disclosed.
Key Facts
- Legal name changed from Cybin Inc. to Helus Pharma Inc. effective October 1, 2026
- Shareholder approval obtained at annual and special meeting on September 22, 2026
- Ticker symbol remains HELP on Nasdaq and Cboe Canada
- New CUSIP: 423492107; new ISIN: CA4234921076
- No action required from shareholders; outstanding certificates remain valid
- Company remains a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs)
Financial Impact
No financial impact — name change is administrative with no change to capital structure, operations, or financials
Risk Factors
- No material change to business fundamentals; stock may trade on name-change sentiment alone
- Forward-looking statements about transformation to commercial-ready company remain aspirational with no timeline or revenue guidance
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001833141-26-000087 |
| Document: heluspharmainc-mcrxform6xk.htm | 0001833141-26-000087 |
| Document: 0001833141-26-000087-index-headers.html | 0001833141-26-000087 |
| Document: 0001833141-26-000087-index.html | 0001833141-26-000087 |
| Document: 0001833141-26-000087.txt | 0001833141-26-000087 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 3 | $10.11 | awaiting T+20 | — | $10.36 (+2.47%) |
Oct 26, 2026 today | 3 | $10.86 | awaiting T+20 | — | $10.36 (−4.56%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 21, 2026 5d ago | 6-K | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 15, 2026 11d ago | 6-K | $11.05 | awaiting T+20 | — | $10.36 (−6.24%) |
Oct 15, 2026 11d ago | Press Release | $11.05 | awaiting T+20 | — | $10.36 (−6.24%) |
Oct 8, 2026 18d ago | 6-K | $10.72 | awaiting T+20 | — | $10.36 (−3.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers